Published in Cell on October 04, 2002
The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet (2008) 7.65
Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet (2004) 7.50
The meter of metabolism. Cell (2008) 5.71
Early aging and age-related pathologies in mice deficient in BMAL1, the core componentof the circadian clock. Genes Dev (2006) 4.90
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27
A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res (2007) 4.09
Toward a detailed computational model for the mammalian circadian clock. Proc Natl Acad Sci U S A (2003) 3.69
Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. Proc Natl Acad Sci U S A (2007) 3.06
Clocks not winding down: unravelling circadian networks. Nat Rev Mol Cell Biol (2010) 2.95
Metabolism and cancer: the circadian clock connection. Nat Rev Cancer (2009) 2.91
MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. Cell Metab (2015) 2.51
Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol (2005) 2.24
Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. Environ Health Perspect (2007) 2.07
Dysregulation of inflammatory responses by chronic circadian disruption. J Immunol (2010) 2.05
An opposite role for tau in circadian rhythms revealed by mathematical modeling. Proc Natl Acad Sci U S A (2006) 2.02
Healthy clocks, healthy body, healthy mind. Trends Cell Biol (2009) 1.95
Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell (2016) 1.91
Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A (2005) 1.91
The circadian clock and pathology of the ageing brain. Nat Rev Neurosci (2012) 1.90
Circadian control of the immune system. Nat Rev Immunol (2013) 1.90
Circadian clock protein BMAL1 regulates cellular senescence in vivo. Cell Cycle (2011) 1.87
SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell (2013) 1.71
Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging (Albany NY) (2011) 1.61
The mouse as a model for understanding chronic diseases of aging: the histopathologic basis of aging in inbred mice. Pathobiol Aging Age Relat Dis (2011) 1.56
Genome-wide transcriptional analysis of the human cell cycle identifies genes differentially regulated in normal and cancer cells. Proc Natl Acad Sci U S A (2008) 1.53
Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci U S A (2005) 1.52
Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci (2006) 1.52
Deficiency in PER proteins has no effect on the rate of spontaneous and radiation-induced carcinogenesis. Cell Cycle (2013) 1.49
Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One (2010) 1.45
Time- and exercise-dependent gene regulation in human skeletal muscle. Genome Biol (2003) 1.44
Noninvasive method for assessing the human circadian clock using hair follicle cells. Proc Natl Acad Sci U S A (2010) 1.43
The role of mPer2 clock gene in glucocorticoid and feeding rhythms. Endocrinology (2009) 1.43
The circadian clock Period 2 gene regulates gamma interferon production of NK cells in host response to lipopolysaccharide-induced endotoxic shock. Infect Immun (2006) 1.43
Sleep deprivation reduces proliferation of cells in the dentate gyrus of the hippocampus in rats. J Physiol (2003) 1.39
Increased vascular senescence and impaired endothelial progenitor cell function mediated by mutation of circadian gene Per2. Circulation (2008) 1.36
Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood (2005) 1.35
Disruption of the circadian clock due to the Clock mutation has discrete effects on aging and carcinogenesis. Cell Cycle (2008) 1.35
A role for the clock gene per1 in prostate cancer. Cancer Res (2009) 1.35
Loss of cryptochrome reduces cancer risk in p53 mutant mice. Proc Natl Acad Sci U S A (2009) 1.35
NONO couples the circadian clock to the cell cycle. Proc Natl Acad Sci U S A (2012) 1.34
The circadian cycle: daily rhythms from behaviour to genes. EMBO Rep (2005) 1.34
Breast cancer and circadian disruption from electric lighting in the modern world. CA Cancer J Clin (2013) 1.31
Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat (2007) 1.30
A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One (2009) 1.29
Disturbed clockwork resetting in Sharp-1 and Sharp-2 single and double mutant mice. PLoS One (2008) 1.28
The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci (2013) 1.28
Biochemical analysis of the canonical model for the mammalian circadian clock. J Biol Chem (2011) 1.27
The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res (2008) 1.27
Genetic differences in human circadian clock genes among worldwide populations. J Biol Rhythms (2008) 1.27
Mouse period 2 mRNA circadian oscillation is modulated by PTB-mediated rhythmic mRNA degradation. Nucleic Acids Res (2008) 1.27
The protective role of Per2 against carbon tetrachloride-induced hepatotoxicity. Am J Pathol (2008) 1.26
Stress sensitivity in metastatic breast cancer: analysis of hypothalamic-pituitary-adrenal axis function. Psychoneuroendocrinology (2006) 1.25
Age-related changes in mesenchymal stem cells derived from rhesus macaque bone marrow. Aging Cell (2011) 1.24
The daily timing of gene expression and physiology in mammals. Dialogues Clin Neurosci (2007) 1.24
bHLH-PAS proteins in cancer. Nat Rev Cancer (2013) 1.23
The clock genes Period 2 and Cryptochrome 2 differentially balance bone formation. PLoS One (2010) 1.22
Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res (2009) 1.22
Comparative analysis of microarray data identifies common responses to caloric restriction among mouse tissues. Mech Ageing Dev (2007) 1.22
The chronobiology, etiology and pathophysiology of obesity. Int J Obes (Lond) (2010) 1.22
Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors. Neoplasia (2007) 1.21
Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer (2007) 1.21
Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. J Pineal Res (2011) 1.20
Circadian clock control of the cellular response to DNA damage. FEBS Lett (2010) 1.20
Circadian clock genes as modulators of sensitivity to genotoxic stress. Cell Cycle (2005) 1.20
Deficiency of circadian protein CLOCK reduces lifespan and increases age-related cataract development in mice. Aging (Albany NY) (2010) 1.19
Nuclear Proteomics Uncovers Diurnal Regulatory Landscapes in Mouse Liver. Cell Metab (2016) 1.17
Circadian clock and cell cycle gene expression in mouse mammary epithelial cells and in the developing mouse mammary gland. Dev Dyn (2006) 1.15
Inducible and reversible Clock gene expression in brain using the tTA system for the study of circadian behavior. PLoS Genet (2007) 1.15
Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. Genome Biol (2008) 1.15
Effect of feeding regimens on circadian rhythms: implications for aging and longevity. Aging (Albany NY) (2010) 1.14
Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. Cancer Res (2009) 1.13
Circadian rhythms influence hematopoietic stem cells. Curr Opin Hematol (2009) 1.12
Structural and functional analyses of PAS domain interactions of the clock proteins Drosophila PERIOD and mouse PERIOD2. PLoS Biol (2009) 1.12
Krüppel-like factor 9 is a circadian transcription factor in human epidermis that controls proliferation of keratinocytes. Proc Natl Acad Sci U S A (2012) 1.12
Emerging links between the biological clock and the DNA damage response. Chromosoma (2007) 1.12
Expression of the gene for Dec2, a basic helix-loop-helix transcription factor, is regulated by a molecular clock system. Biochem J (2004) 1.11
Phase locking and multiple oscillating attractors for the coupled mammalian clock and cell cycle. Proc Natl Acad Sci U S A (2014) 1.11
Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nat Rev Neurosci (2013) 1.11
Circadian clocks and cell division: what's the pacemaker? Cell Cycle (2010) 1.10
Segregation of expression of mPeriod gene homologs in neurons and glia: possible divergent roles of mPeriod1 and mPeriod2 in the brain. Hum Mol Genet (2009) 1.10
The LARK RNA-binding protein selectively regulates the circadian eclosion rhythm by controlling E74 protein expression. PLoS One (2007) 1.08
Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res (2008) 1.05
Regulation and modulation of electric waveforms in gymnotiform electric fish. J Comp Physiol A Neuroethol Sens Neural Behav Physiol (2006) 1.04
Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1. Mol Cell Biol (2004) 1.03
Small molecule modifiers of circadian clocks. Cell Mol Life Sci (2012) 1.03
Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res (2010) 1.02
Entrainment of the mammalian cell cycle by the circadian clock: modeling two coupled cellular rhythms. PLoS Comput Biol (2012) 1.02
The effect of food intake on gene expression in human peripheral blood. Hum Mol Genet (2010) 1.02
Circadian clock function is disrupted by environmental tobacco/cigarette smoke, leading to lung inflammation and injury via a SIRT1-BMAL1 pathway. FASEB J (2013) 1.02
The circadian clock gates the intestinal stem cell regenerative state. Cell Rep (2013) 1.02
The circadian mutation PER2(S662G) is linked to cell cycle progression and tumorigenesis. Cell Death Differ (2011) 1.02
Glucocorticoids play a key role in circadian cell cycle rhythms. PLoS Biol (2007) 1.01
Loss of corepressor PER2 under hypoxia up-regulates OCT1-mediated EMT gene expression and enhances tumor malignancy. Proc Natl Acad Sci U S A (2013) 1.00
Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle (2014) 1.00
Circadian rhythm connections to oxidative stress: implications for human health. Antioxid Redox Signal (2013) 1.00
Does "clock" matter in prostate cancer? Cancer Epidemiol Biomarkers Prev (2006) 0.99
Altered behavioral and metabolic circadian rhythms in mice with disrupted NAD+ oscillation. Aging (Albany NY) (2011) 0.98
Differentiated embryo-chondrocyte expressed gene 1 regulates p53-dependent cell survival versus cell death through macrophage inhibitory cytokine-1. Proc Natl Acad Sci U S A (2012) 0.98
Period 2 regulates neural stem/progenitor cell proliferation in the adult hippocampus. BMC Neurosci (2009) 0.98
Effect of circadian clock mutations on DNA damage response in mammalian cells. Cell Cycle (2012) 0.98
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov (2009) 10.32
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10
Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol (2011) 8.34
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
ROS stress in cancer cells and therapeutic implications. Drug Resist Updat (2004) 5.20
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood (2007) 4.91
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Redox regulation of cell survival. Antioxid Redox Signal (2008) 4.33
Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res (2005) 3.79
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Efficient and specific modifications of the Drosophila genome by means of an easy TALEN strategy. J Genet Genomics (2012) 2.98
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature (2003) 2.81
Mitochondrial defects in cancer. Mol Cancer (2002) 2.75
Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res (2013) 2.73
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol (2006) 2.68
Structural basis of transcription activation: the CAP-alpha CTD-DNA complex. Science (2002) 2.67
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.64
TALEN-mediated precise genome modification by homologous recombination in zebrafish. Nat Methods (2013) 2.64
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol (2012) 2.59
KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.55
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med (2005) 2.30
Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J (2005) 2.25
Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res (2004) 2.24
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res (2005) 2.22
Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem (2003) 2.19
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res (2005) 2.16
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res (2006) 2.15
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res (2011) 2.12
Evaluating concordance to American Diabetes Association standards of care for type 2 diabetes through group visits in an uninsured or inadequately insured patient population. Diabetes Care (2003) 2.09
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res (2012) 2.07
The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr (2007) 2.07
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol (2003) 1.99
Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorg Med Chem (2006) 1.96
CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. Mol Cell (2008) 1.94
Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res (2007) 1.91
Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther (2004) 1.89
Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. J Histochem Cytochem (2006) 1.88
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood (2008) 1.86
Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology (2010) 1.86
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer (2011) 1.80
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res (2007) 1.79
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A (2009) 1.76
Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia (2003) 1.76
Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood (2003) 1.72
K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res (2011) 1.72
Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog (2009) 1.71
ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol (2009) 1.70
Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther (2009) 1.69
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer (2008) 1.69
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med (2010) 1.65
Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem (2005) 1.64
Tissue macroarray: a simple and cost-effective method for high-throughput studies. Appl Immunohistochem Mol Morphol (2003) 1.61
UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution. Pathology (2014) 1.61
Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst (2008) 1.61
REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle (2009) 1.60
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate (2011) 1.58
TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res (2013) 1.56
Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol (2005) 1.56
Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (2011) 1.56
The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer (2006) 1.55
RGD-conjugated dendrimer-modified gold nanorods for in vivo tumor targeting and photothermal therapy. Mol Pharm (2010) 1.55
Increasing physical activity among church members: community-based participatory research. Am J Prev Med (2007) 1.54
Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol (2009) 1.53
Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res (2008) 1.53
Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells. J Biol Chem (2008) 1.52
Misregulated Wnt/beta-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res (2005) 1.51
Preoperative alpha blockade for normotensive pheochromocytoma: is it necessary? J Hypertens (2011) 1.50
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol (2005) 1.48
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle (2010) 1.48
Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem (2011) 1.48
Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer (2007) 1.48
Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Res (2004) 1.47
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res (2014) 1.46
Cautionary note regarding the use of CIs obtained from Kaplan-Meier survival curves. J Clin Oncol (2008) 1.46
Early detection of ovarian cancer: promise and reality. Cancer Treat Res (2002) 1.45
Photosensitizer-loaded gold vesicles with strong plasmonic coupling effect for imaging-guided photothermal/photodynamic therapy. ACS Nano (2013) 1.44
Group visits: promoting adherence to diabetes guidelines. J Gen Intern Med (2007) 1.44
Vulvar Langerhans cell histiocytosis: a case report and review of the literature. Gynecol Oncol (2003) 1.43
CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res (2010) 1.42
Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Res (2009) 1.42
Cancer metabolism: is glutamine sweeter than glucose? Cancer Cell (2010) 1.41